MX2020000693A - Compuestos de 1,8-naftiridinona, y usos de los mismos. - Google Patents

Compuestos de 1,8-naftiridinona, y usos de los mismos.

Info

Publication number
MX2020000693A
MX2020000693A MX2020000693A MX2020000693A MX2020000693A MX 2020000693 A MX2020000693 A MX 2020000693A MX 2020000693 A MX2020000693 A MX 2020000693A MX 2020000693 A MX2020000693 A MX 2020000693A MX 2020000693 A MX2020000693 A MX 2020000693A
Authority
MX
Mexico
Prior art keywords
compounds
naphthyridinone
naphthyridinone compounds
find
oncology
Prior art date
Application number
MX2020000693A
Other languages
English (en)
Inventor
Sarvajit Chakravarty
Son Minh Pham
Jiyun Chen
Amantullah Ansari
Pradeep S Jadhavar
Varshavekumar S Patil
Farha Khan
Sreekanth A Ramachandran
Anil Kumar Agarwal
Original Assignee
Nuvation Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvation Bio Inc filed Critical Nuvation Bio Inc
Publication of MX2020000693A publication Critical patent/MX2020000693A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proveen compuestos de 1,8-naftiridinona como moduladores de un receptor de adenosina; los compuestos pueden encontrar uso como agentes terapéuticos para el tratamiento de enfermedades mediadas a través de una vía de señalización de receptores acoplados a proteína G, y pueden encontrar uso particular en oncología.
MX2020000693A 2017-07-18 2018-07-18 Compuestos de 1,8-naftiridinona, y usos de los mismos. MX2020000693A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762534185P 2017-07-18 2017-07-18
PCT/US2018/042776 WO2019018583A1 (en) 2017-07-18 2018-07-18 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2020000693A true MX2020000693A (es) 2020-07-29

Family

ID=65014549

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000693A MX2020000693A (es) 2017-07-18 2018-07-18 Compuestos de 1,8-naftiridinona, y usos de los mismos.

Country Status (12)

Country Link
US (2) US10793561B2 (es)
EP (1) EP3654982A4 (es)
JP (1) JP2020527593A (es)
KR (1) KR20200040764A (es)
CN (1) CN111093666A (es)
AU (1) AU2018302178A1 (es)
BR (1) BR112020000962A2 (es)
CA (1) CA3070073A1 (es)
IL (1) IL272055A (es)
MX (1) MX2020000693A (es)
SG (1) SG11202000431PA (es)
WO (1) WO2019018583A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019018584A1 (en) 2017-07-18 2019-01-24 GiraFpharma LLC HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
SG11202000431PA (en) * 2017-07-18 2020-02-27 Nuvation Bio Inc 1,8-naphthyridinone compounds and uses thereof
WO2020150676A1 (en) * 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
AU2020208644A1 (en) 2019-01-18 2021-08-26 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
JP2022517811A (ja) * 2019-01-18 2022-03-10 ニューベイション・バイオ・インコーポレイテッド 化合物およびそれらの使用
EP4146345A2 (en) 2020-05-05 2023-03-15 Teon Therapeutics, Inc. Cannabinoid receptor type 2 (cb2) modulators and uses thereof
CN117062818A (zh) * 2021-03-05 2023-11-14 南京再明医药有限公司 新型sos1抑制剂及其制备方法和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
CN103265477B (zh) 2003-02-26 2017-01-11 苏根公司 作为蛋白激酶抑制剂的氨基杂芳基化合物
EP1608622A4 (en) 2003-03-24 2009-04-01 Merck & Co Inc BIARYLSUBSTITUTED 6-LOW HETEROCYCLES AS SODIUM CHANNEL BLOCKERS
RU2006118325A (ru) 2003-10-27 2007-12-10 Астеллас Фарма Инк. (Jp) Производные пиразина и их фармацевтическое применение
ATE452890T1 (de) * 2003-11-04 2010-01-15 Merck & Co Inc Substituierte naphthyridinonderivate
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
GB0800741D0 (en) 2008-01-16 2008-02-20 Univ Greenwich Cyclic triazo and diazo sodium channel blockers
PE20091720A1 (es) 2008-03-31 2009-11-26 Genentech Inc Compuestos de benzopirano y benzoxepina como inhibidores de pi3k
TW201102065A (en) * 2009-05-29 2011-01-16 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
MX352415B (es) 2010-02-05 2017-11-22 Heptares Therapeutics Ltd Star Derivados de 1, 2, 4-triazin-4-amina.
SG186989A1 (en) * 2010-07-14 2013-02-28 Novartis Ag Ip receptor agonist heterocyclic compounds
JP5843869B2 (ja) * 2010-09-24 2016-01-13 アドヴィナス・セラピューティックス・リミテッド アデノシン受容体拮抗薬としての縮合三環化合物
JP2014520394A (ja) 2011-06-09 2014-08-21 ノヴァレッド・アクチエンゲゼルシャフト 有機電子素子のための化合物
CN104053659B (zh) 2012-01-13 2016-11-09 诺华股份有限公司 用于治疗肺动脉高压(pah)及相关病症的作为ip 受体激动剂的稠合的吡咯类
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
CN105377851B (zh) 2013-03-11 2018-07-20 密执安州立大学董事会 Bet布罗莫结构域抑制剂和使用这些抑制剂的治疗方法
EP3842424A1 (en) 2013-03-15 2021-06-30 The Trustees of Columbia University in the City of New York Map kinase modulators and uses thereof in the tretament of tauopathies
EA035601B1 (ru) 2013-06-21 2020-07-14 Зенит Эпидженетикс Лтд. Бициклические ингибиторы бромодомена
CN104341386A (zh) 2013-07-23 2015-02-11 中国科学院上海药物研究所 一类芳基杂环小分子化合物、其衍生物及其制备方法和用途
US9745297B2 (en) 2013-07-30 2017-08-29 Boehringer Ingelheim International Gmbh Compounds as modulators of RORC
AU2014348191B2 (en) 2013-11-18 2019-03-28 Forma Therapeutics Inc. Tetrahydroquinoline compositions as BET bromodomain inhibitors
US9422281B2 (en) 2013-11-18 2016-08-23 Forma Therapeutics, Inc. Benzopiperazine compositions as BET bromodomain inhibitors
JP2017511801A (ja) 2014-02-28 2017-04-27 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン ＢＥＴブロモドメイン阻害剤としての９Ｈ−ピリミド［４，５−ｂ］インドールおよび関連類似体
MX2016013851A (es) 2014-04-23 2017-07-14 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h) -onas como inhibidores de proteinas de bromodominio y extra terminal (bet).
CA2961807A1 (en) * 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
JP6779204B2 (ja) 2014-11-18 2020-11-04 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ａ２ａ拮抗薬特性を有するアミノピラジン化合物
CA2966449A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
US10307407B2 (en) 2015-02-27 2019-06-04 The Regents Of The University Of Michigan 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors
CN107709298A (zh) 2015-06-16 2018-02-16 奥赖恩公司 作为溴结构域抑制剂的螺[环丁烷‑1,3’‑二氢吲哚]‑2’‑酮衍生物
CN108348521B (zh) 2015-08-11 2021-12-03 诺华股份有限公司 用于治疗癌症的5-溴-2,6-二-(1h-吡唑-1-基)嘧啶-4-胺
CN106478651B (zh) * 2015-08-31 2019-07-09 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
MX2018003432A (es) 2015-09-21 2018-06-08 Plexxikon Inc Compuestos heterociclicos y usos de los mismos.
CN108137541B (zh) 2015-09-22 2021-07-06 葛兰素史克知识产权第二有限公司 用于用作溴结构域抑制剂的吡啶酮二甲酰胺
EP3393475A4 (en) 2015-12-24 2019-08-14 Corvus Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
JP7106462B2 (ja) 2016-07-01 2022-07-26 ジー１ セラピューティクス， インコーポレイテッド Ｎ－（ヘテロアリール）－ピロロ［３，２－ｄ］ピリミジン－２－アミンの合成
CN109789143A (zh) 2016-07-01 2019-05-21 G1治疗公司 基于嘧啶的抗增殖剂
GB201612092D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
WO2018081863A1 (en) 2016-11-04 2018-05-11 University Of Wollongong 6-SUBSTITUTED DERIVATIVES OF HEXAMETHYLENE AMILORIDE AS INHIBITORS OF uPA AND USES THEREOF
CN116768859A (zh) 2017-01-20 2023-09-19 艾库斯生物科学有限公司 用于治疗癌症相关疾病的唑嘧啶
TWI801372B (zh) 2017-03-30 2023-05-11 比利時商艾特歐斯比利時有限公司 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法
PL3601296T3 (pl) 2017-03-30 2022-10-10 iTeos Belgium SA Pochodne 2-okso-tiazolowe jako inhibitory i związki a2a do stosowania w leczeniu nowotworów złośliwych
CN107221611B (zh) 2017-06-15 2019-02-05 江西冠能光电材料有限公司 一种稳定易加工有机半导体材料及其有机发光器件应用
CN110809577A (zh) 2017-06-30 2020-02-18 雷沃医疗有限公司 腺苷a2a受体的调节剂
SG11202000431PA (en) * 2017-07-18 2020-02-27 Nuvation Bio Inc 1,8-naphthyridinone compounds and uses thereof
WO2019018584A1 (en) 2017-07-18 2019-01-24 GiraFpharma LLC HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
MX2020004837A (es) 2017-11-06 2020-08-13 Corvus Pharmaceuticals Inc Inhibidores de la vía de adenosina para el tratamiento del cáncer.
CN109810111B (zh) 2017-11-20 2023-10-27 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
EP3723754A4 (en) 2017-12-13 2021-05-19 Merck Sharp & Dohme Corp. IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
MX2020006612A (es) 2017-12-20 2020-11-09 Betta Pharmaceuticals Co Ltd Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
WO2019134539A1 (zh) 2018-01-05 2019-07-11 四川科伦博泰生物医药股份有限公司 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
EP3741758A1 (en) 2018-01-16 2020-11-25 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Bromodomain inhibitor compound and use thereof
CA3088381A1 (en) 2018-01-29 2019-08-01 Beta Pharma, Inc. 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
CA3089159A1 (en) 2018-02-06 2019-08-15 Jiangsu Hengrui Medicine Co., Ltd. Pyrazolo[1,5-a][1,3,5]triazine-2-amine derivative, preparation method therefor and medical use thereof
MA51875A (fr) 2018-02-13 2020-12-23 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
WO2019158070A1 (zh) 2018-02-15 2019-08-22 杭州阿诺生物医药科技有限公司 A2a和/或a2b受体拮抗剂
US11479555B2 (en) 2018-02-23 2022-10-25 Newave Pharmaceutical Inc. Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
CN117903140A (zh) 2018-02-27 2024-04-19 因赛特公司 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
US20200405723A1 (en) 2018-02-28 2020-12-31 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
CA3089746A1 (en) 2018-03-09 2019-09-12 Recurium Ip Holdings, Llc Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors

Also Published As

Publication number Publication date
JP2020527593A (ja) 2020-09-10
US10793561B2 (en) 2020-10-06
US20190023702A1 (en) 2019-01-24
EP3654982A4 (en) 2021-04-14
IL272055A (en) 2020-03-31
AU2018302178A1 (en) 2020-02-13
US20220220111A1 (en) 2022-07-14
SG11202000431PA (en) 2020-02-27
EP3654982A1 (en) 2020-05-27
CN111093666A (zh) 2020-05-01
KR20200040764A (ko) 2020-04-20
CA3070073A1 (en) 2019-01-24
WO2019018583A1 (en) 2019-01-24
BR112020000962A2 (pt) 2020-07-14

Similar Documents

Publication Publication Date Title
MX2020000690A (es) Compuestos heterociclicos como antagonistas de adenosina.
MX2020000693A (es) Compuestos de 1,8-naftiridinona, y usos de los mismos.
NZ737399A (en) Ccr2 modulators
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
PH12017501857A1 (en) Pd-l1 antagonist combination treatments
SA518391624B1 (ar) Ror- منظمات جاما
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
MY195244A (en) Muscarinic Agonists
MX2020001236A (es) Compuestos aza biciclicos como agonistas del receptor muscarinico m1.
MY187540A (en) Compounds active towards bromodomains
MY145305A (en) Cyclopropyl amines as modulators of the histamine h3 receptor
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
MX2017011206A (es) Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
MX2021008650A (es) Compuestos heterociclicos como antagonistas de adenosina.
MX2021006901A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
MX2018005544A (es) Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer.
MX2016015630A (es) Nuevos compuestos.
MX2023000677A (es) Compuestos moduladores de receptor de estrogeno.
SG10201803112RA (en) Liquid treatment apparatus
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.